NAD+ (Nicotinamide Adenine Dinucleotide) Dosage Guide

Evidence-based protocols for the central coenzyme of cellular energy metabolism — IV infusion, subcutaneous injection, and oral precursor (NMN, NR) dosing for longevity, sirtuin activation, DNA repair, and mitochondrial function.

Compiled by PeptideWiki Editorial Team·Last reviewed February 24, 2026

A leading innovator in research chemicals.

All products HPLC tested

|Exclusive Offer

Coupon

10%

Off

Use our affiliate link and code PEPTIDEWIKI at checkout to unlock your 10% discount, every time you use the code.

Shop Now

For research purposes only. PeptideWiki may earn a commission at no extra cost to you.

Research Peptides

NAD+

For research purposes only. PeptideWiki may earn a commission at no extra cost to you.

What Is NAD+?

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell in the body. It is essential for life — without NAD+, cells cannot produce energy, repair DNA, or regulate the gene expression programs that keep them healthy. NAD+ functions as an electron carrier in mitochondrial respiration (the process that converts food into cellular energy), a required cofactor for sirtuins (SIRT1–SIRT7, the “longevity enzymes” that regulate aging, inflammation, and stress resistance), and a substrate for PARP enzymes (which detect and repair DNA damage).

NAD+ is not technically a peptide — it is a dinucleotide (two nucleotides joined by phosphate groups). However, it occupies a central position in the longevity and biohacking community that overlaps heavily with peptide use. NAD+ is routinely administered alongside peptides like MOTS-c, SS-31, Epitalon, and others in comprehensive anti-aging protocols. Peptide clinics commonly offer NAD+ IV infusions and subcutaneous injections as part of their service menu. For these reasons, this guide is included in the dosage guide library.

The critical problem is that NAD+ levels decline significantly with age. Research suggests an approximately 50% reduction between ages 40 and 60. This decline is driven by increased NAD+ consumption (rising CD38 enzyme activity, increased PARP-mediated DNA repair demands) and decreased NAD+ production (declining NAMPT biosynthetic enzyme activity). The resulting NAD+ deficit contributes to mitochondrial dysfunction, impaired DNA repair, reduced sirtuin activity, and many of the hallmarks of biological aging.

Use our Peptide Dosage to calculate your exact subcutaneous NAD+ dose based on vial size and concentration.

Dosing information in this guide is derived from clinical protocols, published research, and community experience and community protocols.

Key Characteristics:

Central coenzyme in cellular energy metabolism — essential electron carrier in mitochondrial oxidative phosphorylation; without NAD+, cells cannot produce ATP efficiently
Sirtuin cofactor (SIRT1–SIRT7) — required for all sirtuin enzymatic activity; sirtuins regulate aging, inflammation, stress resistance, DNA repair, and metabolic homeostasis
PARP substrate for DNA repair — PARP1 and PARP2 enzymes consume NAD+ to detect and repair single-strand DNA breaks; a major NAD+ sink that increases with age and DNA damage
CD38-related metabolism and age-related decline — CD38 enzyme activity increases with age and inflammation, consuming NAD+ at an accelerating rate; a primary driver of age-related NAD+ depletion
Multiple supplementation strategies — IV infusion (direct NAD+), subcutaneous injection (direct NAD+), oral precursors (NMN, NR, niacin, niacinamide) that cells convert to NAD+
Approximately 50% decline between ages 40–60 — progressive NAD+ deficit contributes to mitochondrial dysfunction, impaired DNA repair, reduced sirtuin activity, and biological aging

New to peptides and longevity compounds? Start with the Beginner's Guide to Peptides.

How NAD+ Dosage Is Determined

NAD+ dosing is informed by a combination of clinical practice protocols (IV infusion clinics), published pharmacokinetic studies on oral precursors (NMN, NR), basic biochemistry research on NAD+ metabolism, and extensive community experience. The evidence base is stronger for oral precursors (multiple human clinical trials) than for injectable NAD+ (primarily clinic-based observational data).

NAD+ Metabolomics & Age-Related Decline

Foundational research by Camacho-Pereira et al. and others established that CD38 enzyme activity is a primary driver of age-related NAD+ decline. As CD38 expression increases with age and chronic inflammation, it consumes NAD+ at an accelerating rate. Simultaneously, NAMPT (the rate-limiting enzyme in NAD+ biosynthesis from nicotinamide) activity declines. These findings established the rationale for NAD+ repletion strategies and informed target levels for supplementation.

Oral Precursor Clinical Trials

Multiple human clinical trials have evaluated NMN and NR supplementation. NR (as Niagen) has the longest clinical track record, with studies by Martens et al. and Dollerup et al. demonstrating that 1,000 mg/day NR safely elevates NAD+ blood levels by 40–90% in healthy adults. NMN studies (Yi et al., Yoshino et al.) have shown that 250 mg/day NMN increases blood NAD+ metabolites and improves insulin sensitivity in postmenopausal women with prediabetes. These trials inform the standard oral precursor dose ranges.

IV & SubQ Clinical Protocols

IV NAD+ dosing protocols originated in addiction medicine (the BR+NAD protocol for substance use disorders) and have been adapted by longevity and wellness clinics. Doses of 250–1,000 mg infused over 2–8 hours represent the clinical standard. Subcutaneous NAD+ injection protocols (100–200 mg, 2–3x per week) have been developed as a more practical alternative to IV, allowing home administration with fewer side effects.

Sirtuin & PARP Biochemistry

Sirtuins (SIRT1–SIRT7) are NAD+-dependent deacylase enzymes that regulate hundreds of proteins involved in aging, metabolism, inflammation, and stress resistance. Their activity is directly proportional to NAD+ availability. Similarly, PARP1 consumes one molecule of NAD+ for each DNA repair event. In aging cells with increased DNA damage, PARP activity consumes more NAD+, creating a competitive deficit for sirtuin function. Supplementation aims to restore NAD+ levels high enough to support both DNA repair and sirtuin activity simultaneously.

Strength of evidence: Strong for oral precursors, moderate for injectable. NMN and NR have multiple published human clinical trials demonstrating safety, pharmacokinetics, and NAD+ elevation in humans. IV and SubQ NAD+ have strong clinical practice support but fewer controlled trials. The biochemistry of NAD+ metabolism, sirtuin function, and age-related decline is well-established. Overall, this is one of the better-evidenced compounds in the longevity space.

Standard NAD+ Dosage Ranges

NAD+ supplementation spans a wide range of routes and formulations. The optimal choice depends on your goals, budget, tolerance for side effects, and whether you have access to clinical supervision. Oral precursors are the most accessible; IV infusion is the most intensive.

IV Infusion (Clinical)

Level	Dose per Session	Infusion Time	Frequency	Notes
Starting	250 mg	2–3 hours	1x per week	First-time patients; assess tolerance to infusion
Standard	500 mg	3–4 hours	1–2x per week	Most common clinical protocol for longevity
High / Therapeutic	750–1,000 mg	4–8 hours	Per protocol	Addiction recovery, neurodegenerative support; requires slow drip

Subcutaneous Injection

Level	Dose per Injection	Frequency	Weekly Total	Notes
Starting	50–100 mg	2x per week	100–200 mg	Assess tolerance; injection site stinging is common
Standard	100–200 mg	2–3x per week	200–600 mg	Most common SubQ maintenance protocol
Higher Range	200 mg	Daily or near-daily	Up to 1,000+ mg	Aggressive protocols; typically short-term loading phases

Oral Precursors (NMN & NR)

Precursor	Starting Dose	Standard Dose	Higher Range	Timing
NMN	250 mg/day	500 mg/day	1,000 mg/day	Morning; with or without food
NR (Niagen)	300 mg/day	300–600 mg/day	600–1,000 mg/day	Morning; with or without food
Niacin (NA)	50 mg/day	100–500 mg/day	1,000+ mg/day	With food; causes flushing at higher doses
Niacinamide (NAM)	250 mg/day	500 mg/day	1,000 mg/day	With food; no flushing; may inhibit sirtuins at high doses

Intramuscular (IM) injection: Some clinics offer intramuscular NAD+ injections at 100–200 mg per injection. IM delivery is similar to SubQ but absorbs somewhat faster due to higher muscle blood flow. The side effect profile is comparable. IM is less common than SubQ for home administration because SubQ is easier to self-administer.

Administration Routes Compared

Choosing the right NAD+ route involves balancing efficacy, convenience, cost, and side effects. Each approach has a legitimate place in longevity protocols depending on individual needs and circumstances.

Parameter	IV Infusion	Subcutaneous	Oral Precursors	Intranasal
Typical Dose	250–1,000 mg	100–200 mg	250–1,000 mg/day	50–100 mg (experimental)
NAD+ Elevation	Highest acute spike	Significant	Moderate, sustained	Unknown (limited data)
Side Effects	Flushing, nausea, chest tightness (rate-dependent)	Injection site stinging/redness	Very mild (GI upset rare)	Nasal irritation
Cost	$250–$1,000+ per session	$100–$300/month	$30–$100/month	Varies widely
Convenience	Lowest (clinic visit, 2–4 hrs)	Moderate (home self-injection)	Highest (daily pill)	High (nasal spray)
Supervision Required	Yes (clinic/practitioner)	Recommended initially	No	No
Best For	Acute loading, addiction recovery, neuro support	Maintenance, home protocol	Long-term daily longevity	Experimental/niche
Evidence Base	Clinical practice, limited trials	Clinical practice	Multiple human clinical trials	Minimal

The “load and maintain” approach: Many longevity practitioners use a combination strategy: an initial loading phase of IV NAD+ infusions (e.g., 2–4 sessions over 1–2 weeks) to rapidly restore NAD+ levels, followed by long-term maintenance with SubQ NAD+ injections (2–3x/week) and/or daily oral precursors (NMN or NR). This combines the acute potency of IV with the sustainability and convenience of other routes.

Oral Precursors: NMN vs NR

For most people pursuing NAD+ supplementation, oral precursors are the practical long-term solution. The two most popular options are NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). Both raise intracellular NAD+ levels through the natural salvage biosynthetic pathway, but they enter the pathway at different points.

Feature	NMN	NR (Niagen)
Full Name	Nicotinamide mononucleotide	Nicotinamide riboside
Pathway Position	One step before NAD+ (NMN → NAD+)	Two steps before NAD+ (NR → NMN → NAD+)
Standard Dose	250–1,000 mg/day	300–600 mg/day
Human Clinical Trials	Multiple (growing body of evidence)	More published trials (longer track record)
Community Popularity	Currently more popular	Well-established, slightly less trendy
Regulatory Status (US)	Supplement status contested (FDA challenge)	FDA-recognized as GRAS
Absorption	Debated; may require Slc12a8 transporter or conversion to NR	Well-characterized oral absorption via ENTs
Notable Research	Sinclair lab (Harvard), Yoshino et al.	Brenner lab (ChromaDex), Martens et al.
Side Effects	Very mild (rare GI upset)	Very mild (rare GI upset)

Other NAD+ Precursors

Niacin (nicotinic acid, NA): The oldest and cheapest NAD+ precursor. Highly effective at raising NAD+ but causes dose-dependent skin flushing (histamine release) that many people find intolerable. Extended-release niacin reduces flushing but carries liver toxicity risk at high doses. Use 100–500 mg/day if tolerated.
Niacinamide (nicotinamide, NAM): Another vitamin B3 form that raises NAD+ without flushing. However, high doses of niacinamide may actually inhibit sirtuin activity (nicotinamide is a sirtuin inhibitor at high concentrations), which counteracts one of the primary goals of NAD+ supplementation. Best kept at moderate doses (500 mg/day or less).
Tryptophan (de novo pathway): The amino acid tryptophan can be converted to NAD+ through the de novo synthesis pathway (via the kynurenine pathway). This is a minor contributor to total NAD+ production and not a practical supplementation strategy for meaningful NAD+ elevation.

Bottom line on NMN vs NR: Both work. Both are well-tolerated. NMN is more popular currently and has strong recent research momentum. NR has a longer human clinical trial track record and clearer regulatory acceptance. If one is significantly cheaper or more available in your market, choose that one. Consistent daily use matters more than which precursor you pick.

Calculate Your NAD+ Dose

For subcutaneous NAD+ injection, the compound is typically supplied as a pre-mixed solution (e.g., 100 mg/mL or 200 mg/mL) or as a lyophilized powder for reconstitution. The calculation is straightforward once you know your concentration. For oral precursors (NMN, NR), dosing is pre-measured in capsules — no reconstitution math is needed.

Worked Example (Subcutaneous NAD+):

Vial concentration: 200 mg/mL (pre-mixed)
Target dose: 100 mg
Volume to draw: 100 ÷ 200 = 0.5 mL = 50 units on an insulin syringe

Quick Reference — SubQ NAD+ Injection

Vial Concentration	50 mg Dose	100 mg Dose	200 mg Dose
100 mg/mL	50 units (0.5 mL)	100 units (1.0 mL)	Split into 2 injections
200 mg/mL	25 units (0.25 mL)	50 units (0.5 mL)	100 units (1.0 mL)
400 mg/mL	12.5 units (0.125 mL)	25 units (0.25 mL)	50 units (0.5 mL)

SubQ NAD+ stings. Unlike most peptide injections, subcutaneous NAD+ commonly causes a stinging or burning sensation at the injection site that can last several minutes. This is normal and not a sign of a problem. Injecting slowly, using a smaller volume (higher concentration), and icing the area beforehand can reduce discomfort. The stinging diminishes for most users after the first few injections.

Skip the Math — Use Our

Enter your vial concentration and desired dose — get instant calculations with zero manual math.

NAD+ Dosage by Goal

NAD+ supplementation serves multiple goals depending on your health status, age, and priorities. The optimal route and dose vary by objective. Below are the most common goal-specific protocols.

General Longevity & Anti-Aging Maintenance

The most common use case. The goal is to sustainably restore NAD+ levels closer to youthful baselines, supporting sirtuin activity, DNA repair capacity, and mitochondrial function on an ongoing basis. Oral precursors are the mainstay for this goal due to their convenience, safety, and affordability for long-term daily use.

Route: Oral NMN or NR (daily)
Dose: NMN 500 mg/day or NR 300–600 mg/day
Timing: Morning dosing preferred
Duration: Ongoing (indefinite daily supplementation)
Adjunct: TMG 500–1,000 mg/day as a methyl donor
Stack: + Epitalon for telomere/pineal support; + MOTS-c for mitochondrial optimization

Energy & Mitochondrial Optimization

For individuals experiencing fatigue, brain fog, or declining exercise capacity associated with aging or metabolic dysfunction. The goal is to maximize mitochondrial NAD+ availability for ATP production through oxidative phosphorylation.

Route: Oral NMN 500–1,000 mg/day + optional SubQ NAD+ 100–200 mg 2x/week
Duration: 8–12 weeks, then reassess
Stack: + MOTS-c 5 mg SubQ 3–5x/week (mitochondrial-derived peptide that enhances AMPK activation and metabolic function); + SS-31 for cardiolipin stabilization and mitochondrial membrane integrity

Cognitive Enhancement & Neuroprotection

NAD+ is critical for neuronal energy metabolism and sirtuin-mediated neuroprotection. Age-related cognitive decline correlates with falling brain NAD+ levels. Higher-dose protocols and more aggressive routes (IV or SubQ) are often used for cognitive goals.

Route: IV NAD+ 500 mg (loading: 2–4 sessions over 2 weeks) + oral NMN 500–1,000 mg/day (maintenance)
Duration: IV loading phase, then ongoing oral maintenance
Stack: + Dihexa (neurotrophic support) or Semax/Selank (neuropeptide stack for cognitive function)

Addiction Recovery & Neuroregeneration

High-dose IV NAD+ has been used in addiction medicine protocols (notably the BR+NAD protocol) for substance use disorder recovery. The hypothesis is that restoring depleted neuronal NAD+ supports brain energy metabolism, reduces cravings, and accelerates recovery of damaged neural pathways. This is a clinical application requiring medical supervision.

Route: IV NAD+ 500–1,000 mg per session
Frequency: Daily for 7–14 days (induction)
Infusion time: 4–8 hours per session (slow drip essential)
Maintenance: Weekly or biweekly IV sessions, transitioning to SubQ/oral
Setting: Medical clinic only — not a home protocol

DNA Repair & Genomic Integrity

PARP enzymes are among the largest consumers of NAD+ in the cell, using it to repair DNA single-strand breaks. In aging cells with accumulated DNA damage, PARP activity can deplete NAD+ to the point where sirtuin function is compromised. Restoring NAD+ levels ensures both DNA repair pathways and sirtuin-mediated genomic maintenance can operate simultaneously.

Route: Oral NMN 500–1,000 mg/day + optional SubQ NAD+ 100 mg 2–3x/week
Duration: Ongoing (DNA damage accumulates continuously)
Stack: + Epitalon (telomerase activation for telomere maintenance); + SS-31 (mitochondrial ROS reduction to decrease oxidative DNA damage)

Match the intensity to the goal. General longevity maintenance requires only affordable daily oral precursors. Acute therapeutic goals (addiction recovery, severe cognitive decline, rapid NAD+ repletion) justify the cost and inconvenience of IV infusion. SubQ NAD+ sits in the middle — more potent than oral, more convenient than IV. Most people will get the best value from consistent daily oral NMN or NR supplementation.

Cycling & Duration

NAD+ supplementation differs from most peptides in that the primary use case (longevity maintenance) involves continuous, long-term daily use rather than defined on/off cycles. NAD+ is a naturally occurring molecule in every cell, and the goal is to restore depleted levels to a physiological range — not to pulse a signaling molecule. That said, different routes and goals call for different duration strategies.

Protocol	Duration	Cycling	Notes
Oral NMN/NR (Maintenance)	Ongoing (indefinite)	No cycling required	Daily use is standard; NAD+ levels drop when supplementation stops
SubQ NAD+ (Maintenance)	Ongoing or periodic	Optional: 8 weeks on, 4 weeks off	Some practitioners cycle SubQ; others use continuously alongside oral
IV NAD+ (Loading Phase)	1–2 weeks (2–4 sessions)	Transition to SubQ/oral after	Used for rapid NAD+ repletion; not meant for indefinite weekly use
IV NAD+ (Therapeutic)	7–14 consecutive days	Per clinical protocol	Addiction recovery; medical supervision required
Periodic IV Boosters	1 session every 4–8 weeks	Alongside daily oral maintenance	Some users do periodic IV sessions as a “boost” on top of daily oral supplementation

NAD+ is not like GHRPs: Growth hormone releasing peptides require strict cycling because their target receptors (GHS-R1a) desensitize with continuous stimulation. NAD+ does not work through receptor binding at the cell surface. It is a metabolic cofactor consumed by enzymes (sirtuins, PARPs, CD38). There is no receptor desensitization mechanism. NAD+ levels simply fall when supplementation stops because the underlying age-related consumption (CD38, PARP) continues. This is why continuous daily oral supplementation is the standard approach for longevity.

When to Reassess Your Protocol

After 8–12 weeks of oral precursor use, assess subjective improvements (energy, cognition, sleep quality) and consider blood NAD+ testing if available through your provider.
If side effects develop, reduce dose or switch routes. Oral precursors at standard doses are extremely well-tolerated; side effects are more common with injectable routes.
If no subjective improvement after 8 weeks of oral NMN/NR at standard doses, consider increasing the dose, adding SubQ NAD+, or addressing other factors (sleep, exercise, chronic inflammation) that impair NAD+ metabolism.
Annual review: As you age, NAD+ consumption increases. Reassess your dose and protocol annually, ideally with NAD+ blood level testing when available.

NAD+ Stacking Protocols

NAD+ is a foundational molecule that synergizes with multiple peptides and compounds in the longevity space. Because NAD+ supports mitochondrial function, sirtuin activity, and DNA repair, it enhances the effectiveness of peptides that target these same pathways through complementary mechanisms.

NAD+ + MOTS-c — The Mitochondrial Optimization Stack

MOTS-c is a mitochondrial-derived peptide that activates AMPK (the cellular energy sensor) and enhances metabolic function. Combined with NAD+ (which fuels the electron transport chain), this stack provides dual-pathway mitochondrial support: NAD+ feeds the ETC while MOTS-c activates AMPK to optimize metabolic efficiency and insulin sensitivity.

Compound	Dose	Route	Purpose
NAD+ (NMN)	500–1,000 mg/day	Oral (daily)	Mitochondrial ETC fuel; sirtuin activation; DNA repair substrate
MOTS-c	5 mg, 3–5x per week	SubQ	AMPK activation; metabolic optimization; insulin sensitivity

NAD+ + SS-31 — Mitochondrial Membrane Integrity Stack

SS-31 (elamipretide) targets the inner mitochondrial membrane, binding to cardiolipin to stabilize the electron transport chain complexes and reduce reactive oxygen species production. NAD+ provides the electron-carrying capacity that these stabilized complexes need to function. Together, they optimize both the structure and fuel supply of the mitochondrial energy system.

Compound	Dose	Route	Purpose
NAD+ (NMN)	500–1,000 mg/day	Oral (daily)	ETC electron carrier; sirtuin cofactor; overall NAD+ repletion
SS-31	5–10 mg/day	SubQ	Cardiolipin stabilization; ETC complex integrity; ROS reduction

NAD+ + Epitalon — The Longevity & Telomere Stack

Epitalon (epithalon) is a tetrapeptide that activates telomerase, the enzyme that maintains telomere length at chromosome ends. NAD+ supports the sirtuin and PARP activities that maintain genomic integrity. This stack addresses two complementary aspects of cellular aging: telomere attrition (Epitalon) and NAD+-dependent genomic maintenance (sirtuins, PARPs).

Compound	Dose	Route	Purpose
NAD+ (NMN)	500–1,000 mg/day	Oral (daily, ongoing)	Sirtuin activation; PARP-mediated DNA repair; metabolic support
Epitalon	5–10 mg/day for 10–20 days	SubQ (cycled 2–3x/year)	Telomerase activation; pineal gland support; melatonin regulation

NAD+ + Metformin — A Note on Timing

Metformin is a widely used anti-aging compound that activates AMPK (similar to MOTS-c) and is being studied in the TAME (Targeting Aging with Metformin) trial. Both metformin and NAD+ precursors are common in longevity stacks. However, some research suggests that metformin may blunt the exercise-induced benefits of NMN/NR by interfering with mitochondrial complex I (the same complex that NAD+ feeds as NADH). Many practitioners recommend separating metformin and NMN/NR dosing by several hours, or taking metformin on non-exercise days, to avoid potential interference.

NAD+ is foundational, not redundant. NAD+ does not duplicate what peptides like MOTS-c, SS-31, or Epitalon do. It provides the metabolic substrate (the fuel) that these peptides' target pathways require to function. Stacking NAD+ with mitochondrial and longevity peptides is not additive — it is synergistic. Without adequate NAD+, sirtuins cannot deacylate, PARPs cannot repair DNA, and the electron transport chain cannot produce ATP efficiently, regardless of what other compounds are present.

Explore more combinations with our Peptide Stack Builder or browse the Top 10 Peptide Stacks guide.

Safety, Side Effects & Contraindications

Safety Profile Overview: Oral NAD+ precursors (NMN, NR) have excellent safety profiles supported by multiple human clinical trials. Side effects are rare and mild. IV and SubQ NAD+ have more pronounced acute side effects (especially IV — flushing, nausea, chest tightness during infusion) but these are rate-dependent and transient. The primary theoretical concern is whether NAD+ repletion could support existing cancer cell metabolism. Overall, NAD+ supplementation is one of the better-tolerated interventions in the longevity space.

IV NAD+ Infusion Side Effects

Common and rate-dependent:

Flushing — warmth and redness, particularly in the face and chest; the most common side effect; resolves when infusion rate is slowed
Chest tightness / pressure — a sensation of tightness or heaviness in the chest; rate-dependent and resolves with slower infusion; not cardiac in origin
Nausea and abdominal cramping — common at faster infusion rates; can be managed by slowing the drip
Anxiety or restlessness — some patients report a feeling of unease or jitteriness during the infusion; typically transient
Headache — reported by some patients, usually mild
Light-headedness — ensure adequate hydration before and during infusion

All IV side effects are rate-dependent — they worsen when the infusion is too fast and resolve when it is slowed. A well-managed infusion at an appropriate rate should be tolerable, though some discomfort (mild flushing, warmth) is normal even at slow rates.

SubQ NAD+ Injection Side Effects

Injection site stinging/burning — the most common SubQ side effect; NAD+ solution causes a noticeable sting upon injection that can last several minutes; diminishes with repeated use
Injection site redness or swelling — mild and transient; standard for subcutaneous injections
Mild flushing or warmth — less pronounced than IV but possible, especially at higher doses

Oral Precursor Side Effects (NMN, NR)

Very mild overall — human clinical trials report minimal side effects at standard doses
Rare mild GI upset (nausea, bloating) — usually resolves with food or dose adjustment
Possible sleep disruption if taken late in the day — take in the morning to avoid
Niacin (NA) specifically causes flushing at doses above 50–100 mg — this is a histamine-mediated response unique to the niacin form, not NMN or NR

The cancer question: All rapidly dividing cells (including cancer cells) require NAD+ for their metabolism. There is a theoretical concern that boosting systemic NAD+ could provide metabolic fuel to existing tumors. However, NAD+-dependent sirtuins also have tumor-suppressive functions, and PARP-mediated DNA repair prevents the mutations that cause cancer. Current evidence does not establish that NAD+ supplementation increases cancer risk in healthy individuals, but the prudent approach is to avoid high-dose NAD+ repletion if you have a known active malignancy. Discuss with an oncologist.

Contraindications

Active malignancy — theoretical concern that NAD+ repletion could support cancer cell metabolism. Discuss with an oncologist before supplementing.
Pregnancy and breastfeeding — insufficient safety data for NAD+ supplementation (beyond normal dietary vitamin B3 intake) during pregnancy or nursing. Avoid injectable NAD+ entirely; discuss oral precursors with your OB/GYN.
Bleeding disorders or anticoagulant therapy — NAD+ may interact with PARP inhibitors and other medications; consult your prescribing physician.
Liver disease — high-dose niacin (not NMN/NR) carries liver toxicity risk; avoid extended-release niacin formulations in particular. NMN and NR do not share this concern at standard doses.

When to Stop or Reduce Dose

Persistent GI symptoms that do not resolve with dose adjustment or timing changes
Sleep disruption that persists despite morning dosing — reduce dose or discontinue
Any allergic reaction (rash, hives, swelling) — discontinue and consult a provider
New cancer diagnosis — stop supplementation and discuss with oncologist
IV infusion: persistent severe discomfort despite appropriate infusion rate adjustment — switch to SubQ or oral route

Common NAD+ Dosing Mistakes

Avoid these common errors to get the most out of your NAD+ protocol:

Running IV NAD+ infusion too fast: The most common cause of severe side effects (intense flushing, nausea, chest tightness, anxiety) during IV NAD+ is an infusion rate that is too fast. NAD+ must be infused slowly over 2–4 hours. Clinics that rush the infusion to save time dramatically increase patient discomfort. Always insist on a slow, controlled drip rate and do not hesitate to ask the clinic to slow down further if symptoms are uncomfortable.

Expecting oral NAD+ (the molecule itself) to work like oral NMN/NR: Oral NAD+ (the full molecule) has poor bioavailability because it is broken down in the GI tract before it can be absorbed intact. NAD+ precursors (NMN, NR) are specifically designed to be absorbed orally and then converted to NAD+ inside cells. If taking an oral supplement, use NMN or NR — not NAD+ itself. If you want direct NAD+, use IV or SubQ routes.

Neglecting consistent daily dosing with oral precursors: NAD+ is consumed continuously by cells for energy metabolism, DNA repair, and sirtuin activity. Sporadic supplementation with NMN or NR will not sustain elevated NAD+ levels. Daily, consistent dosing is essential for meaningful long-term benefits. Missing doses frequently undermines the entire protocol.

Ignoring the cancer concern in high-risk individuals: While NAD+ supplementation appears safe for healthy individuals, those with known active malignancies should exercise caution. Cancer cells require NAD+ for their metabolism. High-dose NAD+ repletion could theoretically support tumor growth. Discuss NAD+ supplementation with an oncologist if you have a cancer history or active diagnosis.

Skipping methyl donor support (TMG) during high-dose precursor use: High-dose NMN or NR supplementation increases nicotinamide turnover, which requires methylation for clearance. Without adequate methyl donor intake (TMG, folate, B12), this could theoretically deplete methyl groups and raise homocysteine. Adding TMG 500–1,000 mg/day is a simple precautionary measure recommended by several researchers in the field.

Choosing the most expensive route without considering goals: IV NAD+ is the most expensive option ($250–$1,000+ per session) and is not necessarily the best choice for everyone. For general longevity and maintenance, oral NMN or NR (pennies per day) is usually sufficient. SubQ NAD+ offers a middle ground. Reserve IV NAD+ for specific clinical indications (neurodegenerative support, addiction recovery protocols, acute cognitive enhancement) rather than defaulting to it because it sounds more powerful.

Not storing NAD+ solution properly after reconstitution: Reconstituted NAD+ for subcutaneous injection should be stored refrigerated (2–8°C) and protected from light. NAD+ is sensitive to degradation at room temperature and in the presence of light. Use bacteriostatic water for reconstitution and discard any reconstituted solution after 4 weeks.

Taking NMN/NR at night and disrupting sleep: NAD+ plays a role in circadian rhythm regulation, and some users report that taking NMN or NR too late in the day causes wakefulness or disrupted sleep. The most commonly recommended timing is morning dosing (with or without food, depending on the formulation). If you experience sleep disruption, move your dose to the morning.

Frequently Asked Questions

Key Takeaways

NAD+ is a central coenzyme in cellular energy, DNA repair, and aging — it declines ~50% between ages 40–60, contributing to mitochondrial dysfunction and biological aging
Not technically a peptide — NAD+ is a dinucleotide, but it is widely used in the peptide/longevity community and stacked with peptides like MOTS-c, SS-31, and Epitalon
Multiple supplementation routes: IV infusion (highest acute elevation, most side effects, most expensive), SubQ injection (moderate, home administration), oral precursors NMN/NR (most practical for daily long-term use)
Oral precursors are the mainstay for most people: NMN 500 mg/day or NR 300–600 mg/day, taken in the morning, with TMG as a methyl donor adjunct
IV NAD+ is rate-sensitive: flushing, nausea, and chest tightness are common but resolve by slowing the infusion rate; always insist on a slow drip
SubQ NAD+ stings but is well-tolerated: 100–200 mg, 2–3x/week is the standard home protocol
Best longevity stacks: NAD+ + MOTS-c (mitochondria), NAD+ + SS-31 (cardiolipin), NAD+ + Epitalon (telomeres)
No cycling needed for oral precursors — NAD+ is a metabolic cofactor, not a receptor agonist; continuous daily use is standard
Cancer concern is theoretical but worth noting — avoid high-dose NAD+ repletion with active malignancies; discuss with an oncologist
Strong evidence base — multiple human clinical trials for NMN and NR; well-established biochemistry; one of the better-evidenced longevity interventions

This article is for educational and informational purposes only. See our Disclaimer.

References

Camacho-Pereira J, et al. “CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism.” Cell Metab. 2016;23(6):1127-1139. PubMed
Yoshino J, et al. “NAD+ intermediates: the biology and therapeutic potential of NMN and NR.” Cell Metab. 2018;27(3):513-528. PubMed
Martens CR, et al. “Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults.” Nat Commun. 2018;9(1):1286. PubMed
Dollerup OL, et al. “A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin sensitivity, and lipid-mobilizing effects.” Am J Clin Nutr. 2018;108(2):343-353. PubMed
Yi L, et al. “The efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial.” GeroScience. 2023;45(1):29-43. PubMed
Yoshino M, et al. “Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.” Science. 2021;372(6547):1224-1229. PubMed
Imai S, Guarente L. “NAD+ and sirtuins in aging and disease.” Trends Cell Biol. 2014;24(8):464-471. PubMed
Verdin E. “NAD+ in aging, metabolism, and neurodegeneration.” Science. 2015;350(6265):1208-1213. PubMed
Rajman L, et al. “Therapeutic potential of NAD-boosting molecules: the in vivo evidence.” Cell Metab. 2018;27(3):529-547. PubMed
Grant R, et al. “A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD+.” Front Aging Neurosci. 2019;11:257. PubMed

Next Steps

Continue your research with these resources.

MOTS-c Dosage Guide

Learn dosing protocols for MOTS-c — the mitochondrial-derived peptide that pairs synergistically with NAD+ for metabolic optimization.

Read Guide

Dosage Calculator

Calculate your exact subcutaneous NAD+ dose based on vial concentration and desired milligrams.

Open Calculator

Peptide Directory

Browse all peptides with research summaries and dosing data.

View Directory